STAT+: Breast cancer pill from AstraZeneca misses mark in pivotal trial
A pill from AstraZeneca failed to improve outcomes in closely watched breast cancer study, a result that could limit the use of the medicine.
AstraZeneca's breast cancer pill, camizestrant, has failed in a pivotal trial as a first-line therapy for advanced tumors, according to STAT News. The drug, when combined with another medication, did not outperform standard treatment in terms of how long patients survived before their cancer progressed. This setback could limit the use of the medicine, as the SERENA-4 trial, which enrolled patients with ER-positive, HER2-negative advanced cancer, did not meet its success criteria.
The trial's failure could diminish the potential market for the drug, which had previously received accelerated approval in the U.S. for patients with tumors that developed a specific mutation indicating drug resistance.
Brief written by urgent.news from STAT News's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
